Pharnext is opening their first US study sites for a phase III trial in a rare neuropathy – a milestone in the development of Pharnext’s leading candidate.
Based in Paris (France), Pharnext is developing new therapies for neurological conditions, including rare diseases such as Charcot-Marie-Tooth Disease.
Pharnext uses network pharmacology to discover synergistic combinations of drugs (Pleodrugs) that can have a therapeutic effect in a given disease. As the components drugs are already approved, development is faster – meaning bypassing phase I trials is possible.
PXT3003 is now in phase III trials (PLEO-CMT), which expects to enroll 300 patients with Charcot-Marie-Tooth Disease Type 1A (CMT1A). Enrolment will progress during 2016, with the first US site now being opened in Saint-Louis University (Missouri).